Clinical trials: Cholangiocarcinoma Cancer
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
Cholangiocarcinoma
Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma
Cholangiocarcinoma, is a malignant gastrointestinal tumor of low incidence with a poor prognosis. Chemotherapy is the most common treatment for advanced disease.
- Trial name
- 4CC (NCT02456714)
- Testing
- FOLFIRINOX
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cholangiocarcinoma
S-1 in Combination With Abraxane in Treating Cholangiocarcinoma
This phase II study was designed to evaluate the efficacy and safety of S-1 plus Abraxane as second-line treatment for cholangiocarcinoma.
- Trial name
- NCT01963325
- Testing
- S-1 plus Abraxane
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yuhong Li
Uterine Cervical Neoplasms, Endometrial Neoplasms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected…
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms
- Trial name
- NCT05007106
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib
- Where
- 73 sites in United States, Canada and 13 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Cholangiocarcinoma Resectable
Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA
Biliary tract cancer is a highly aggressive and heterogeneous group of gastrointestinal cancers that arise from the intra- or extrahepatic bile ducts (CCA), or the gallbladder (GBC)(1-3).
- Trial name
- NEOLANGIO (NCT06569225)
- Testing
- Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma, Cholangiocarcinoma
Targeted Navigation in Hepatocellular Carcinoma (HCC)
The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatobiliary Cancer
- Trial name
- NCT06260943
- Testing
- Target Navigation Pilot Program
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- University of Miami
Intrahepatic Cholangiocarcinoma (Icc)
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking.
- Trial name
- EXOMIC (NCT07224737)
- Testing
- EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- City of Hope Medical Center
Mesothelioma, Uveal Melanoma
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
- Conditions
- Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03207347
- Testing
- Niraparib
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Florida
Advanced Malignant Solid Tumor, Solid Tumor Cancer
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer.
- Trial name
- NCT07337525
- Testing
- PLT012
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pilatus Biosciences Inc
Biliary Tract Cancer, Cholangiocarcinoma
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
Study consisted of an open-label, safety run-in part and a randomized, double-blind, placebo-controlled Phase 2/3 part. In the Phase 2/3 part, the study was evaluated whether bintrafusp alfa in combination with the current…
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT04066491
- Testing
- M7824, Gemcitabine, Cisplatin
- Where
- 99 sites in United States, Argentina and 13 more
- Volunteers
- 309 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Colorectal Carcinoma, Gastric Adenocarcinoma
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX).
- Conditions
- Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04430738
- Testing
- tucatinib, trastuzumab, oxaliplatin
- Where
- 27 sites in United States, Japan
- Volunteers
- 40 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Pancreatic Cancer, Cholangiocarcinoma
Bilioenteric Anastomosis by Magnetic Compressive Technique
The purpose of this study is to determine whether the magnetic compressive anastomosis has a better outcomes than traditional manual anastomosis on bilioenteric anastomosis.
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Bile Duct Injury, Choledochal Cyst
- Trial name
- BAMCT (NCT03774589)
- Testing
- Magnetic Compressive Anastomosis, Manual Anastomosis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Intrahepatic Cholangiocarcinoma
Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients
The purpose of this study is to confirm that prognosis of Intrahepatic Cholangiocarcinoma (ICC) with resection and radiotherapy ,to find which is safe and effective treatment.
- Trial name
- NCT01914289
- Testing
- Resection, Radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003296
- Testing
- filgrastim, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Brown University
Intrahepatic Cholangiocarcinoma
HAIC Versus Systemic Chemotherapy for Unresectable ICC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin compared systemic chemotherapy of gemcitabine and…
- Trial name
- NCT03771846
- Testing
- irinotecan, oxaliplatin , fluorouracil, and leucovorin, gemcitabine and oxaliplatin
- Where
- 2 sites in China
- Volunteers
- 188 people
- Sponsor
- Shi Ming
Colorectal Cancer, Pancreatic Cancer
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Trial name
- NCT04421820
- Testing
- BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 220 people
- Sponsor
- Bold Therapeutics, Inc.
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Intrahepatic Cholangiocarcinoma
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is associated with poor prognosis. This study aims to explore the efficacy and safety FOLFOX-HAIC in combination with targeted therapy and/or PD-1 inhibitors for patients with initially…
- Trial name
- NCT05489692
- Testing
- hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.